Evidence map›Paper›PMID 32528296›Full record

SynthesisFrontiers in pharmacology2020

Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer's Disease: A Bayesian Network Meta-Analysis.

Tingting Zhang, Nanyang Liu, Hongfu Cao, Wei Wei, Lina Ma, Hao Li

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Subcutaneous application ofFrontiers in public health · 2026
    Observational
  8. Review
  9. Antidementia Medication Use in Nursing Home Residents.Journal of geriatric psychiatry and neurology · 2024
    Article
  10. Review
  11. Article
  12. GinkgoDB: an ecological genome database for the living fossil, Ginkgo biloba.Database : the journal of biological databases and curation · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tingting ZhangCollege of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Nanyang LiuDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.
Hongfu CaoInstitute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Science, Beijing, China.
Wei WeiCollege of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Lina MaDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.
Hao LiDepartment of Geratology, Xiyuan Hospital, China Academy of Chinese Medical Science, Beijing, China.
China Academy of Chinese Medical Sciences · CNShandong University of Traditional Chinese Medicine · CNXiyuan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPharmacological treatments play a significant role in treating mild to moderate Alzheimer's disease (AD), but the optimal doses of various drugs used for these treatments are unknown. Our study compared the efficacy, acceptability, and safety of different doses of pharmacological treatments for mild to moderate AD.

methodsRandomized controlled trials (RCTs) were identified by searching the PubMed, EMBASE, and Cochrane Library databases (all RCTs published from the date of inception of the databases until September 19, 2019). Trials comparing the efficacy, acceptability, and safety of pharmacological interventions involving donepezil, galantamine, rivastigmine, memantine, huperzine A, and

resultsOur meta-analysis included 37 studies involving 14,705 participants. In terms of improving cognitive function, galantamine 32 mg, galantamine 24 mg, donepezil 5 mg, and donepezil 10 mg were more effective than other interventions, with the surface under the cumulative ranking curve (SUCRA) values of 93.2, 75.5, 73.3, and 65.6%, respectively. According to the SUCRA values, EGb761 240 mg was considered to be the optimal intervention in terms of both acceptability and safety. With regard to clinical global impression, rivastigmine 12 mg had the highest probability of being ranked first (83.7%). The rivastigmine 15 cm

conclusionsDifferent doses of the tested pharmacological interventions yielded benefits with regard to cognition, acceptability, safety, function, and clinical global impressions, but not effective behaviors.

Indexed as

Alzheimer’s diseasedonepezilnetwork meta-analysispharmacological treatmentrandomized controlled trial

Identifiers

PMID32528296
PMCPMC7264393
OpenAlexW3029122459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.